Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE LID 2: ADS-5102 Safety Study in LID
NCT02202551Phase 3Completed
- Start
- Jul 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of amantadine in levodopa-induced dyskinesia (LID). Primary endpoint: Number of Participants With Reported Adverse Events and Safety-Related Study Drug Discontinuations up to 101 weeks. Started Jul 2014; status: completed.
02
Drugs
amantadine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT02202551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202551.